Adaptas Solutions to Acquire Applied Kilovolts and Analytical Instrumentation Business from L3Harris Technologies

IN.PACT AV Drug-Coated Balloon Is First and Only to Show Superior and Sustained Results Through Two Years Compared to PTA in Treating Arteriovenous Fistulae Lesions

The data, which were presented virtually as a podium first at the 2021 Charing Cross Symposium, demonstrated that the IN.PACT™ AV drug-coated balloon (DCB) is the first and only DCB to show sustained and superior effectiveness through two years compared to standard percutaneous transluminal angioplasty (PTA) in end-stage renal disease (ESRD) patients with de novo or non-stented restenotic native arteriovenous fistulae (AVF) in the upper extremity.

Martell Diagnostic Laboratories Announces HERTEST: Groundbreaking Way to Detect Effectiveness of Breast Cancer RX Globally

HERTEST is a blood test that looks for a protein called human epidermal growth factor receptor (HER2), which is shed into the blood stream of patients with growing breast cancer tumors.

ESPRIT CAM Improves Productivity for Long Part Machining by Automating Multi-spindle Program Creation

ESPRIT CAM: New computer-aided-manufacturing (CAM) technology has been introduced by ESPRIT CAM, part of Hexagon’s Manufacturing Intelligence division that provides manufacturers with the control and flexibility needed to use multi-spindle and multi-channel computer-numerical-control (CNC) machinery for the machining of long parts.

Today, February 26, 2020 Jay Ray, President and CEO of Adaptas Solutions notes, “These strategic acquisitions expand our mass spectrometer component product offering and allow us to continue to build our market-leading position in mass spectrometry components, subassemblies and contract manufacturing.” Ray added, “Adding the CeraMAX product line allows us to cultivate future innovation for our market-leading mass spectrometry OEM customers.  The Applied Kilovolts business deepens our product offering while expanding our global manufacturing to now include Europe.”

This latest acquisition further enhances Adaptas’ manufacturing and engineering resources, allowing Adaptas to accelerate OEM client development projects while offering the industry’s broadest range of next generation mass spectrometer detection solutions.

Adaptas Solutions is a portfolio company of Ampersand Capital Partners.  Financial terms of the acquisition were not disclosed.  The transaction is expected to close in mid-2020.

spot_img

DON'T MISS

Related Articles